These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179 [TBL] [Abstract][Full Text] [Related]
10. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633 [TBL] [Abstract][Full Text] [Related]
12. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC J Clin Oncol; 2017 Aug; 35(22):2535-2541. PubMed ID: 28489510 [TBL] [Abstract][Full Text] [Related]
14. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph R; Weber JS; Dronca R; Mitchell TC; Patnaik A; Zarour HM; Joshua AM; Zhao Q; Jensen E; Ahsan S; Ibrahim N; Ribas A Ann Oncol; 2019 Apr; 30(4):582-588. PubMed ID: 30715153 [TBL] [Abstract][Full Text] [Related]
15. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph RW; Weber JS; Dronca R; Gangadhar TC; Patnaik A; Zarour H; Joshua AM; Gergich K; Elassaiss-Schaap J; Algazi A; Mateus C; Boasberg P; Tumeh PC; Chmielowski B; Ebbinghaus SW; Li XN; Kang SP; Ribas A N Engl J Med; 2013 Jul; 369(2):134-44. PubMed ID: 23724846 [TBL] [Abstract][Full Text] [Related]
16. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465 [TBL] [Abstract][Full Text] [Related]
17. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115. Robert C; Gastman B; Gogas H; Rutkowski P; Long GV; Chaney MF; Joshi H; Lin YL; Snyder W; Chesney JA Eur J Cancer; 2024 Aug; 207():114120. PubMed ID: 38870745 [TBL] [Abstract][Full Text] [Related]
18. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521 [TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Shimizu T; Seto T; Hirai F; Takenoyama M; Nosaki K; Tsurutani J; Kaneda H; Iwasa T; Kawakami H; Noguchi K; Shimamoto T; Nakagawa K Invest New Drugs; 2016 Jun; 34(3):347-54. PubMed ID: 27000274 [TBL] [Abstract][Full Text] [Related]
20. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]